CG Oncology CGON EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's EPS (diluted)?
- CG Oncology (CGON) reported EPS (diluted) of -$0.71 in Q1 2026.
- How has CG Oncology's EPS (diluted) changed year-over-year?
- CG Oncology's EPS (diluted) decreased by 57.8% year-over-year, from -$0.45 to -$0.71.
- What is the long-term trend for CG Oncology's EPS (diluted)?
- Over 2 years (2023 to 2025), CG Oncology's EPS (diluted) has grown at a -63.6% compound annual growth rate (CAGR), from -$15.62 to -$2.07.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.